Home » Healthcare » Pharmaceuticals » Hepatitis B Vaccine Market

Hepatitis B Vaccine Market By Composition (Combination Vaccines, Mono Vaccines), By End Users Age (Adult Hepatitis B Vaccines, Paediatric Hepatitis B Vaccines) – Growth, Future Prospects And Competitive Analysis 2017 – 2025

Price: $4999

Published: | Report ID: 6603 | Report Format : PDF

Market Insights

Factors such as increased awareness of hepatitis B infection prevention and the fact that governments in many countries have mandated immunization and hepatitis B vaccine inclusion in the national immunization schedule are driving the global market growth for the hepatitis B vaccine.

The report titled “Hepatitis B Vaccine Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall hepatitis B vaccine market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on composition, end users’ ages, and different geographical regions.

In order to help strategic decision-makers, the report also includes sections on the competitive profiling of the leading players in the global hepatitis B vaccine market, attractive investment propositions, and market positioning of key manufacturers.

Geographically, the global hepatitis B vaccine market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global hepatitis B vaccine market.

Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive scenario of the global hepatitis B vaccine market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global hepatitis B vaccine market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global hepatitis B vaccine market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on composition, the global hepatitis B vaccine market is segmented as follows:

  • Mono Vaccines
  • Combination Vaccines

Hepatitis B is a life-threatening liver infection caused by the hepatitis B virus. A vaccine is more effective than any other treatment at preventing infection. According to the WHO (World Health Organization), the prevalence of hepatitis B is highest in the Western Pacific and African regions, however, and lowest in the American population. Factors such as an increase in awareness of vaccines are expected to contribute to the market growth of the hepatitis B vaccine globally. For the purposes of this study, the market is divided into segments based on vaccine composition, such as monovalent and combination vaccines. Combination vaccines that protect against multiple pathogens involve the combination of multiple antigens into a single vaccine.

Combination vaccines such as Infanrix Hexa, Hexaci Ma/Hexyon, Twinrix, Ambirix, and Comvax are widely used for the prevention of hepatitis B infection. It is observed that combination vaccines are a major revenue-generating segment. Factors such as higher patient compliance, reduced dose frequency, better disease control, coverage of vaccines under the national immunization program, and reduced chances of missing an immunization are driving the growth of the combination vaccine market globally. It is observed that monovalent vaccines such as RecombiVax HB, Hendrix, and Engerix-B are approved for the treatment of hepatitis B infection.

Based on end-user age group, the global hepatitis B vaccine market is segmented as follows:

  • Vaccines for Adults Against Hepatitis B
  • Pediatric Hepatitis B Vaccines

The Hepatitis B virus causes life-threatening liver disease; the vaccine is more effective than any other treatment in preventing infection. The choice of hepatitis B vaccine varies with age. Adult Hepatitis B Vaccines are used for active immunization of people over the age of 18 and over the age of 21 in Europe and the United States, respectively. Hepatitis B is one of the most common traveler’s diseases, which can be avoided by vaccination. Governments across the world have mandated the immunization of travelers, which is acting as a growth driver for the hepatitis B vaccine market across the world. It is observed that in 2016, adult hepatitis B vaccines held the largest market share, as adults have a high risk of developing hepatitis B infections due to end-stage renal disease, drug abuse, and HIV infection, which is driving the market growth of adult hepatitis B vaccines globally.

In terms of immunogenicity, pediatric vaccines differ from adult vaccines. Pediatric hepatitis B vaccines are used for the prevention of hepatitis B infection in infants, toddlers, and adolescents because babies and young children are at higher risk for developing the potentially fatal complications of the infection. It is estimated that pediatric hepatitis B vaccines will show a steady growth rate during the forecast period. Pediatric vaccines such as Infanrix, Hexa, Hexacima/Hexyon, Ambirix, and Comvax have been linked to adverse reactions. In the market, Infanrix Hexa is widely accepted.

For the purpose of this study, the hepatitis B vaccine market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Hepatitis B is a life-threatening liver disease that can cause acute and chronic liver infections and may lead to cirrhosis and liver cancer. Safe and effective vaccines are available on the market to prevent hepatitis B infection. According to the World Health Organization (WHO), the prevalence of hepatitis B is highest in the Western Pacific, and in the African region, more than 6% of the adult population is affected by hepatitis B infection. In Southeast Asia and the European region, it is estimated that 2% and 1.6% of the general population are affected by hepatitis B, respectively.

The burden of hepatitis B infection is considerably lower in the American population, which represents approximately 0.7% of the overall population. It is observed that in the base year 2016, North America was a major revenue-contributing segment. Factors such as the higher cost of vaccines, immunization programs, and favorable R&D activities are driving market growth in North America. Currently, Asia Pacific is not a major revenue-generating segment, but it is estimated that it will show the highest CAGR during the forecast period. Rising healthcare awareness, populous countries, increased awareness of vaccines, and government initiatives in vaccination programs would influence the growth of the hepatitis B vaccine market in the Asia Pacific region.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Hepatitis B Vaccines Market Snapshot
2.2 Global Hepatitis B Vaccines Market, by Composition, 2016 (US$ Bn)
2.3 Global Hepatitis B Vaccines Market, by End Users Age, 2016 (US$ Bn)
2.4 Global Hepatitis B Vaccines Market Share, by Geography, 2016 (Value %)

Chapter 3 Hepatitis B Vaccines Market Analysis
3.1 Global Hepatitis B Vaccines Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Government initiative in Hepatitis B vaccine Immunization
3.2.2 Challenges
3.2.2.1 Stringent Regulatory Guidelines
3.2.3 Opportunities
3.2.3.1 Increase in Awareness of Hepatitis B Infection and Prevention
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Hepatitis B Vaccines Market

Chapter 4 Global Hepatitis B Vaccines Market, by Composition
4.1 Overview
4.2 Combination Vaccines
4.3 Mono Vaccines

Chapter 5 Global Hepatitis B Vaccines Market, by End Users Age
5.1 Overview
5.2 Adult Hepatitis B vaccines
5.3 Paediatric Hepatitis B vaccines

Chapter 6 Global Hepatitis B Vaccines Market, By Geography
6.1 Preface
6.2 North America (U.S. & Canada)
6.3 Europe (U.K., Germany & Rest of Europe)
6.4 Asia Pacific (China, Japan and Rest of APAC)
6.5 Latin America
6.6 Middle East and Africa

Chapter 7 Company Profiles
7.1 Beijing Minhai Biotechnology
7.2 CSL Limited
7.3 Dynavax Technologies
7.4 Emergent Biosolutions
7.5 GlaxoSmithKline Biologicals
7.6 Merck & Co, Inc.
7.7 Novartis AG
7.8 Pfizer Inc.
7.9 Sanofi Pasteur
7.10 Serum Institute of India
7.11 Sinovac Biotech

List of Figures

FIG. 1 Hepatitis B Vaccines Market: Research Methodology
FIG. 2 Global Hepatitis B Vaccines Market, by Composition, 2016 (US$ Bn)
FIG. 3 Global Hepatitis B Vaccines Market, by End Users Age, 2016 (US$ Bn)
FIG. 4 Global Hepatitis B Vaccines Market Share, by Geography, 2016 (Value %)
FIG. 5 Attractive Investment Proposition: Global Hepatitis B Vaccines Market, by Geography, 2016
FIG. 6 Global Combination Vaccines Market for Hepatitis B Vaccines, 2015 – 2025 (US$ Bn)
FIG. 7 Global Mono Vaccines Market for Hepatitis B Vaccines, 2015 – 2025 (US$ Bn)
FIG. 8 Global Hepatitis B Vaccines Market for Adult Hepatitis B, 2015 – 2025 (US$ Bn)
FIG. 9 Global Hepatitis B Vaccines Market for Paediatric Hepatitis B, 2015 – 2025 (US$ Bn)
FIG. 10 Latin America Hepatitis B Vaccines Market, 2015 – 2025 (US$ Bn)
FIG. 11 Middle East and Africa Hepatitis B Vaccines Market, 2015 – 2025 (US$ Bn)

List of Tables

TABLE 1 Market Positioning of Key Players in Global Hepatitis B Vaccines Market
TABLE 2 Global Hepatitis B Vaccines Market, by Composition, 2015 – 2025 (US$ Bn)
TABLE 3 Global Hepatitis B Vaccines Market, by End Users Age, 2015 – 2025 (US$ Bn)
TABLE 4 Global Hepatitis B Vaccines Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 5 North America Hepatitis B Vaccines Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 6 Europe Hepatitis B Vaccines Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 7 Asia Pacific Hepatitis B Vaccines Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 8 Beijing Minhai Biotechnology: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 9 CSL Limited: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 10 Dynavax Technologies: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 11 Emergent Biosolutions: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 12 GlaxoSmithKline Biologicals: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 13 Merck & Co, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 14 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 15 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 16 Sanofi Pasteur: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 17 Serum Institute of India: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 18 Sinovac Biotech: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)

Frequently Asked Questions

What is the size of Hepatitis B Vaccine Market?

The market for Hepatitis B Vaccine Market is expected to reach US$ 1.89 Bn By 2025.

What is the Hepatitis B Vaccine Market CAGR?

The Hepatitis B Vaccine Market is expected to see significant CAGR growth over the coming years, at 3.5%.

What is the Forecast period considered for Hepatitis B Vaccine Market?

The report is forecasted from 2017-2025.

What is the base year considered for Hepatitis B Vaccine Market?

The base year of this report is 2016.

Who are the major players in this market?

Sanofi Pasteur, Serum Institute of India, Sinovac Biotech, Dynavax Technologies are some of the major players in the global market.

Benzodiazepine Drugs Market

Published:
Report ID: 35263

Molecular Transport Medium Market

Published:
Report ID: 35092

Angiotensin Converting Enzyme (ACE) Inhibitors Market

Published:
Report ID: 12832

Stroke Management Market

Published:
Report ID: 34872

Pulmonary Embolism Market

Published:
Report ID: 34866

Oral Macromolecular Formulation Market

Published:
Report ID: 34861

Metastatic Melanoma Cancer Diagnostics Market

Published:
Report ID: 34855

Cytomegalovirus (CMV) Infection Treatment Market

Published:
Report ID: 4417

Immune Checkpoint Inhibitors Market

Published:
Report ID: 34697

Intraosseous Devices Market

Published:
Report ID: 7197

Dermatophytic Onychomycosis Therapeutics Market

Published:
Report ID: 34653

Africa Pharmaceutical Market

Published:
Report ID: 34584

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN